Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2847PDF: 851HTML: 6525Untitled: 227Untitled: 189Untitled: 205Untitled: 215 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4774PDF: 2840HTML: 2291 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2771PDF: 1121HTML: 3285 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2808PDF: 1010HTML: 5522 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2864PDF: 1442HTML: 3047Cover Letter: 208 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3338PDF: 1474HTML: 4007 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3949PDF: 1511HTML: 9189Untitled: 280Untitled: 187Untitled: 170Untitled: 165Untitled: 183Untitled: 340 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2587PDF: 865HTML: 17564Fig1 Caligaris: 172Fig.2 Caliga: 205 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3999PDF: 1055HTML: 3595Untitled: 177Cneo. Fig.1: 114Untitled: 105Untitled: 127Untitled: 133 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2875PDF: 1235HTML: 2700Figure 1: 173 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3264PDF: 936HTML: 2956 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3309PDF: 1350HTML: 2666 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2513PDF: 840HTML: 8883Efremov 1: 229Efremov 2: 191 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2226PDF: 1050HTML: 1984Characteristic of study group: 200 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2201PDF: 807HTML: 1631Figure 1: 183Table 1: 210 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3071PDF: 878HTML: 7164Kost Fig1: 185Kost Fig 2: 180Kost Fig3: 177Kost Fig 4: 191Kost Fig5: 186Kost fig 6: 174 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9087PDF: 6064HTML: 87964Fig.1b: 186Fig.1c: 190Fig.2a: 178Fig.2b: 177Fig.4: 189Fig.2c: 187Fig.3: 185Tab.1: 228Tab.2: 207Tab.3: 190Tab.4: 224Fig1a: 187 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3898PDF: 757HTML: 1850 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4371PDF: 910HTML: 1326Table1: 181 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2455PDF: 787HTML: 1736 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3514PDF: 891HTML: 1654figure 1: 165Untitled: 190 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2073PDF: 1117HTML: 7698cover letter paper final AML: 214 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2586PDF: 747HTML: 2298 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2300PDF: 1327HTML: 17082Bassan Fig.1: 144Bassan Fig.2: 155Bassan Fig.4: 142Fig.3: 187 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4661PDF: 1325HTML: 1915Untitled: 180Untitled: 176 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4075PDF: 1935HTML: 5268Table 1: 191 -
A STUDY ON THE EXPRESSION OF BCR-ABL TRANSCRIPT IN MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) CASES USING THE REVERSE TRANSCRIPTASE POLYMERASE REACTION ASSAY (RT-PCR) AND ITS CORRELATION WITH HEMATOLOGICAL REMISSION STATUS POST INITIAL INDUCTION THERAPY
1355PDF: 827HTML: 5039INSTITUTE PUBLICATION COMMITTEE APPROVAL: 162 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4328PDF: 1765HTML: 1107







